Average Insider

Where insiders trade, we follow

$FBLG
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Healthcare
Sector
Biotechnology
Industry
Peter O'Heeron
CEO
13
Employees
$1.44
Current Price
$14.17M
Market Cap
52W Low$0.62
Current$1.447.0% above low, 93.0% below high
52W High$12.40

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.

Upcoming Earnings

Scheduled earnings reports
Oct 30, 2026
EPS
Estimated-$0.63
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
No past earnings data available

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.10.9